Latest Revenue Recognition News

Electro Optic Systems (ASX:EOS) reports sustained demand driven by global conflicts, launches MARSS business in Europe, and updates 2026 revenue outlook with base business guidance of $240m to $270m.

Marlin Global’s portfolio lagged the broader market in May 2026, weighed down by semiconductor underexposure and near-term revenue challenges in key holdings, while AI-focused stocks powered a narrow rally.

Austco Healthcare expects FY26 revenue between A$90 million and A$95 million, driven by strong sales and a significant US rollout. Net profit after tax is forecast to jump over 50%, supported by operational growth and a one-off benefit.

Trajan Group Holdings reports steady market demand and successful cost initiatives in H2 FY26 but warns of a $4 million revenue hit from Australian dollar appreciation.

UOA Development Bhd’s Q1 2026 results reveal a decline in revenue and profit compared to last year, despite a solid RM130.7 million in new property sales and a substantial unbilled sales pipeline.

Papyrus Australia has fulfilled a critical contract milestone by delivering 200 biodegradable Collar Keeper product samples to TBS Mining Solutions, enabling the next phase of product testing despite a slight delay.

SKS Technologies has landed a $22 million contract to deliver integrated electrical systems for a major retailer's new Melbourne headquarters, pushing its order book to $355 million amid a booming project pipeline.

Resonance Health upgrades its FY26 underlying EBITDA guidance to $2.6 million, driven by operational efficiencies and growth in its Software-as-Medical Devices segment, despite a slight revenue timing delay.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) temporarily halted trading to relodge its FY25 Annual Report, revealing a $2.86 million loss driven by US market rationalisation and ongoing cost-cutting.

DUG Technology Ltd recorded a 35% revenue increase in FY26-Q3, surpassing full-year FY25 revenue in just nine months and announcing a strategic move to half-year financial reporting.

Control Bionics progresses its scalable distributor-led model in North America, inks a strategic US partnership for iOS speech devices, and gains German reimbursement eligibility for NeuroNode, while managing cash flow amid NDIS delays.

CurveBeam AI reported stable device orders but faces regulatory delays for FDA and China clearances, while securing a A$4 million investment from WEGO Orthopaedics and advancing clinical collaborations with robotic surgery systems.